Compile Data Set for Download or QSAR
Report error Found 238 Enz. Inhib. hit(s) with all data for entry = 8915
TargetTyrosine-protein kinase JAK1(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100348(US8501944, 374 | US8501944, 370 | US9868729, Examp...)
Affinity DataKd:  6.70nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US8501944, 375 | US8501944, 372 | US9868729, Examp...)
Affinity DataKd:  4.70nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100351(US8501944, 376 | US8501944, 373 | US9868729, Examp...)
Affinity DataKd:  14nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100348(US8501944, 374 | US8501944, 370 | US9868729, Examp...)
Affinity DataKd:  5.10nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US8501944, 375 | US8501944, 372 | US9868729, Examp...)
Affinity DataKd:  5.10nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100351(US8501944, 376 | US8501944, 373 | US9868729, Examp...)
Affinity DataKd:  10nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100348(US8501944, 374 | US8501944, 370 | US9868729, Examp...)
Affinity DataKd:  2.90nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US8501944, 375 | US8501944, 372 | US9868729, Examp...)
Affinity DataKd:  2.70nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100351(US8501944, 376 | US8501944, 373 | US9868729, Examp...)
Affinity DataKd:  4.10nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100348(US8501944, 374 | US8501944, 370 | US9868729, Examp...)
Affinity DataKd:  98nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US8501944, 375 | US8501944, 372 | US9868729, Examp...)
Affinity DataKd:  4.5nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100351(US8501944, 376 | US8501944, 373 | US9868729, Examp...)
Affinity DataKd:  9.40nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100348(US8501944, 374 | US8501944, 370 | US9868729, Examp...)
Affinity DataKd:  6.70nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100348(US8501944, 374 | US8501944, 370 | US9868729, Examp...)
Affinity DataKd:  2.90nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100349(US8501944, 371 | US9868729, Example 207 | US105330...)
Affinity DataKd:  11nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100349(US8501944, 371 | US9868729, Example 207 | US105330...)
Affinity DataKd:  3nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US8501944, 375 | US8501944, 372 | US9868729, Examp...)
Affinity DataKd:  4.70nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US8501944, 375 | US8501944, 372 | US9868729, Examp...)
Affinity DataKd:  2.70nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100351(US8501944, 376 | US8501944, 373 | US9868729, Examp...)
Affinity DataKd:  14nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100351(US8501944, 376 | US8501944, 373 | US9868729, Examp...)
Affinity DataKd:  4.10nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US8501944, 375 | US8501944, 372 | US9868729, Examp...)
Affinity DataIC50: 0.800nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US8501944, 375 | US8501944, 372 | US9868729, Examp...)
Affinity DataIC50: 3.20nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365380(US9868729, Example 41 | US10533001, Example 41 | U...)
Affinity DataIC50: 5.5nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US8501944, 375 | US8501944, 372 | US9868729, Examp...)
Affinity DataIC50: 6.70nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US8501944, 375 | US8501944, 372 | US9868729, Examp...)
Affinity DataIC50: 15nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM428864(US10533001, Example 1)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365310(2-(4-(4- acetylpiperazin-1- yl)phenylamino)-4- (cy...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365344(US9868729, Example 34 | US10533001, Example 34 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365346(US9868729, Example 35 | US10533001, Example 35 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365375(US9868729, Example 36 | US10533001, Example 36 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365376(US9868729, Example 37 | US10533001, Example 37 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100348(US8501944, 374 | US8501944, 370 | US9868729, Examp...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365379(US9868729, Example 40 | US10533001, Example 40 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365381(US9868729, Example 42 | US10533001, Example 42 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365384(2-(4-(4-acetylpiperazin-1-yl)phenylamino)-4-(piper...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365391(2-(4-(4-acetyl-2-carbamoylpiperazin-1-yl)phenylami...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365392(US9868729, Example 56 | US10533001, Example 56 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365400(US9868729, Example 67 | US10533001, Example 67 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365402(US9868729, Example 70 | US10533001, Example 70 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365403(US9868729, Example 71 | US10533001, Example 71 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365405(US9868729, Example 73 | US10533001, Example 73 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365406(US9868729, Example 77 | US10533001, Example 77 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365412(US9868729, Example 96 | US10533001, Example 96 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365413(US9868729, Example 97 | US10533001, Example 97 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365414(US9868729, Example 98 | US10533001, Example 98 | U...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US8501944, 375 | US8501944, 372 | US9868729, Examp...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM428925(US10533001, Example 100)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365417(US9868729, Example 101 | US10533001, Example 101 |...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365418(US9868729, Example 103 | US10533001, Example 103 |...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365419(US9868729, Example 104 | US10533001, Example 104 |...)
Affinity DataIC50: 55nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 238 total ) | Next | Last >>
Jump to: